Pulmatrix Issued Patents Covering iSPERSE™ Technology for Treatment of Patients with Inhaled Dry Powders
LEXINGTON, Mass., July 23, 2015 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM) has been granted two patents from the U.S. Patent and Trademark Office (U.S. Patent # 8,992,983 and U.S. patent # 9,061,352), which cover the composition of matter for the Company's underlying iSPERSE™ (inhaled Small Particles Easily Respirable and Emitted) inhaled dry powder technology as well as methods for treating a subject using respirable dry powders. The proprietary combination of salts and amino acids has been engineered to create small and dense particles possessing properties that have the potential to enable or improve new approaches for the treatment of lung disease or facilitate greater efficiency in the delivery of pharmaceuticals to the lungs. The Company now was 36 issued patents worldwide covering the iSPERSE™ technology through at least 2030.
"These issuances build upon previously issued international patents and reflect our aggressive strategy to broadly protect the global IP position of our core iSPERSE™ technology," said Robert W. Clarke, Ph.D., chief executive officer of Pulmatrix. "Our issued and pending patents are the result of the research and development conducted in our labs and which formed the basis for our most advanced clinical-stage candidate, a branded generic bronchodilator for COPD, and our proprietary development candidate, an anti-fungal for cystic fibrosis. We look forward to the receipt of additional patents covering distinct as well as overlapping components and combinations of our iSPERSE™ technology and drug development candidates."
Pulmatrix's iSPERSE™ technology has the potential to solve significant limitations of other inhaled technologies available today, such as nebulizers, metered dose inhalers, and conventional lactose blend dry powder inhalers. iSPERSE™ particles are engineered to be small, dense, and easily dispersible upon inhalation, thereby delivering the drugs more efficiently to the airways. This targeted airway delivery of drugs also reduces systemic exposure and potential side effects. Importantly, unlike other traditional inhalation technologies, iSPERSE™ is also flow rate independent, which should provide reliable dose delivery across patient populations regardless of the status of patient lung function.
"These patent grants further validate the novelty and relevance of the iSPERSE™ technology," said David Hava, Ph.D., chief scientific officer for Pulmatrix. "Specifically, they recognize the uniqueness of our ability to produce aerodynamically small, dense powders that maintain remarkable dispersibility profiles across a range of drug classes and underscore the differentiation of our technology from conventional and earlier particle engineering approaches."
SOURCE Pulmatrix, Inc.
For further information: Tom Baker, 617-532-0624, tbaker@Pulmatrix.com